Search results
Results From The WOW.Com Content Network
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.
Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
Continued adoption of TruWave disposable pressure monitoring devices and progress in transfemoral EVOQUE and SAPIEN M3 platforms are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) delivered earnings and revenue surprises of -7.27% and 1.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Edwards Lifesciences (EW) closed at $111.61 in the latest trading session, marking a -0.68% move from the prior day. Edwards Lifesciences (EW) Stock Moves -0.68%: What You Should Know Skip to main ...
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.